Cited by 67Multiple Sclerosis Research StudiesPeripheral Neuropathies and DisordersAutoimmune Neurological Disorders and Treatments

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Seroprevalence of Aquaporin-4–IgG in a Northern California Population Representative Cohort of Multiple Sclerosis

Abstract

Importance Using an aquaporin-4 (AQP4) M1-isoform-specific enzyme-linked immunosorbent assay (ELISA) and a fixed transfected cell-based assay (CBA), we tested AQP4-IgG in a northern California population representative cohort of 3293 potential cases with multiple sclerosis (MS). Seropositive cases were tested additionally by fluorescence-activated cell sorting, a live transfected cell-based assay. Observations Sera samples were available in 1040 cases; 7 yielded positive results, 4 by ELISA alone and 3 by both ELISA and CBA. Clinical data (episodes of optic neuritis and longitudinally extensive transverse myelitis [reported on at least 1 magnetic resonance imaging spine]) supported the alternative diagnosis of neuromyelitis optica for 2 patients as seropositive by both ELISA and CBA. These 2 patients alone tested positive by a fluorescence-activated cell-sorting assay. The diagnosis of MS was considered correct in the other 5 patients. Thus, 5 ELISA results and 1 fixed CBA result were false positive. Conclusions and relevance Sensitive serological evaluation for AQP4-IgG in this large population-representative cohort of predominantly white non-Hispanic patients with MS reveals that neuromyelitis optica spectrum disorder is rarely misdiagnosed as MS in contemporary US neurological practice (0.2%). The frequency of a false-positive result for ELISA and CBA in this MS cohort were 0.5% and 0.1%, respectively. This finding reflects the superior specificity of CBA and justifies cau…

Overview

Integrity signals

Registry

Crossref · 10.1001/jamaneurol.2014.1581

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Approximately 70% of patients with relapsing NMOSD are AQP4-IgG positive, with the sensitivity increased with the use of cell-based rather than ELISA assays.

    “Approximately 70% of patients with relapsing NMOSD are AQP4-IgG positive, with the sensitivity increased with the use of cell-based rather than ELISA assays.53,54”

    From Diagnosis of multiple sclerosis: progress and challenges (2017) · cites this paper as [54]

  • AQP4-IgG is highly specific for NMOSD, although false positives occur in up to 0.5% of MS patients using ELISA assays, potentially resulting in misdiagnosis.

    “AQP4-IgG is highly specific for NMOSD, although false positives occur in up to 0.5% of MS patients using ELISA assays, potentially resulting in misdiagnosis.54,55”

    From Diagnosis of multiple sclerosis: progress and challenges (2017) · cites this paper as [54]

Citations

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Metadata

Authors
Pittock, S. J., Lennon, V. A., Bakshi, N., Shen, L., McKeon, A., Quach, H., Briggs, F. B. S., Bernstein, A. L., Schaefer, C. A., & Barcellos, L. F.
Affiliations
  • Mayo Clinic (US)
  • The Permanente Medical Group, Oakland, California
  • Kaiser Permanente (US)
  • University of California, Berkeley (US)
  • Palms of Pasadena Hospital (US)
Corresponding author
Pittock, Sean J.
Venue
JAMA Neurology
Published
2014-11-01
Volume
71
Issue
11
Pages
1433
ISSN
2168-6149 (ISSN-L)
OpenAlex
W1988435452
Cited by
67
References
1
Citations by year
2026: 1 · 2025: 1 · 2024: 4 · 2023: 4 · 2022: 6 · 2021: 5 · 2020: 7 · 2019: 9 · 2018: 4 · 2017: 7 · 2016: 11 · 2015: 6 · 2014: 2
FWCI
6.43
Type
journal article
Language
en
Open access
closed
Locations
  • JAMA Neurology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institute of Allergy and Infectious Diseases (R01AI076544)
  • National Institute of Neurological Disorders and Stroke (NS065829, R01NS049510, R01NS065829)
  • National Institute of Environmental Health Sciences (R01ES017080)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
  • Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
  • Health Sciences › Medicine › Clinical Neurology › Autoimmune Neurological Disorders and Treatments
Keywords
aquaporin-4 antibodies, multiple sclerosis, neuromyelitis optica spectrum disorder, seroprevalence, false-positive serology, cell-based assays, ELISA, diagnostic specificity, misdiagnosis, longitudinally extensive transverse myelitis, optic neuritis
MeSH terms
Adult, Aged, Autoantibodies, California, Enzyme-Linked Immunosorbent Assay, Female, Humans, Immunoglobulin G, Male, Middle Aged, Multiple Sclerosis, Myelitis, Transverse, Optic Neuritis, Cohort Studies, Seroepidemiologic Studies, Aquaporin 4

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review